Chemed Corp
NYSE:CHE

  • LAST PRICE
    566.5100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    227.7100/ 1
  • Ask / Lots
    900.7500/ 1
  • Open / Previous Close
    0.0000 / 566.5100
  • Day Range
    ---
  • 52 Week Range
    492.8400
    654.6200
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Apr 26, 2024

  • Apr 24, 2024

      Show headlines and story abstract

    • 5:14PM ET on Wednesday Apr 24, 2024 by MT Newswires
      Companies Mentioned: CHE
      05:14 PM EDT, 04/24/2024 (MT Newswires) -- Chemed (CHE) reported Q1 adjusted earnings late Wednesday of $5.20 per diluted share, up from $4.28 a year earlier. Four analysts surveyed by Capital IQ expected $5.48. Revenue for the quarter ended March 3...

    • 4:19PM ET on Wednesday Apr 24, 2024 by MT Newswires
      Companies Mentioned: CHE
      04:19 PM EDT, 04/24/2024 (MT Newswires) -- ...

    • 4:19PM ET on Wednesday Apr 24, 2024 by MT Newswires
      Companies Mentioned: CHE
      04:19 PM EDT, 04/24/2024 (MT Newswires) -- ...

    • 4:15PM ET on Wednesday Apr 24, 2024 by Dow Jones
      Companies Mentioned: CHE
      =========== ========== Total Admissions 16,911 16,179 Total Discharges 16,170 15,405 Average length of stay (days) 103.9 99.9 Median length of stay (days) 16.0 15.0 ADC by major diagnosis Cerebro 43.6% 41.8% Neurological 13.4 19.3 Cancer 10.1 10.5 Cardio 16.1 16.0 Respiratory 7.2 7.3 Other 9.6 5.1 ----------- ---------- Total 100.0% 100.0% =========== ========== Admissions by major diagnosis Cerebro 27.7% 26.4% Neurological 7.5 10.7 Cancer 24.6 24.7 Cardio 15.6 16.2 Respiratory 10.8 10.9 Other 13.8 11.1 ----------- ---------- Total 100.0% 100.0% =========== ========== Estimated uncollectible accounts as a percent of revenues 1.1% 1.0% Accounts receivable -- Days of revenue outstanding-excluding unapplied Medicare payments 42.3 34.7 Days of revenue outstanding-including unapplied Medicare payments 34.3 29.2 The "Footnotes to Financial Statements" are integral parts of this financial information. CHEMED CORPORATION AND SUBSIDIARY COMPANIES FOOTNOTES TO FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 (unaudited) Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing (a) operations (in thousands): Three Months Ended March 31, 2024 ----------------------------------------------------- VITAS Roto-Rooter Corporate Consolidated ------- --------------- --------- ---------------- Stock option expense $ - $ - $ (9,026) $ (9,026) Severance arrangement - - (5,337) (5,337) Long-term incentive compensation - - (3,784) (3,784) Amortization of reacquired franchise agreements - (2,352) - (2,352) --- ------- ------- -------- Pretax impact on earnings - (2,352) (18,147) (20,499) Excess tax benefits on stock compensation - - 3,297 3,297 Income tax benefit on the above - 548 1,840 2,388 --- ------- ------- -------- After-tax impact on earnings $ - $ (1,804) $(13,010) $ (14,814) === ======= ======= ======== Included in the results of operations for 2023 are the following significant credits/(charges) which may not be indicative of ongoing (b) operations (in thousands): Three Months Ended March 31, 2023 ----------------------------------------------------- VITAS Roto-Rooter Corporate Consolidated ------- --------------- --------- ---------------- Stock option expense $ - $ - $ (8,482) $ (8,482) Long-term incentive compensation - - (2,514) (2,514) Amortization of reacquired franchise agreements - (2,352) - (2,352) Litigation settlements - (1,756) - (1,756) --- ------- ------- -------- Pretax impact on earnings - (4,108) (10,996) (15,104) Excess tax benefits on stock compensation - - 1,650 1,650 Income tax benefit on the above - 1,089 1,763 2,852 --- ------- ------- -------- After-tax impact on earnings $ - $ (3,019) $ (7,583) $ (10,602) === ======= ======= ======== (c) VITAS has 11 large (greater than 450 ADC), 19 medium (greater than 200 but less than 450 ADC) and 20 small (less than 200 ADC) hospice programs. Of Vitas' 30 Medicare provider numbers, for the trailing 12 months, 27 provider numbers have a Medicare cap cushion of greater than 10%, one provider number has a Medicare cap cushion between 5% and 10%, one provider number has a Medicare cap cushion between 0% and 5%, and one provider number has a Medicare cap liability.

Peers Headlines